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ABSTRACT - Purpose: Monocarboxylate transporters (MCT) are proton-coupled integral membrane proteins 
that control the influx and efflux of endogenous monocarboxylates such as lactate, acetate and pyruvate. They 
also transport and mediate the clearance of drugs such as valproate and gamma-hydroxybutyrate. CD147 functions 
as ancillary protein that chaperones MCT1 and MCT4 to the cell membrane. There is limited data on the 
maturation of MCT and CD147 expression in tissues related to drug distribution and clearance. The objective of 
the present study was to quantify hepatic MCT1, MCT4, and CD147 mRNA, whole cell and membrane protein 
expression from birth to sexual maturity. Methods: Liver tissues were collected from male and female Sprague 
Dawley rats at postnatal days (PND) 1, 3, 5, 7, 10, 14, 18, 21, 28, 35, and 42 (n = 3 - 5). Hepatic mRNA, total and 
membrane protein expression of MCT1, MCT4, and CD147 was evaluated via qPCR and western blot. Results: 
MCT1 mRNA and protein demonstrated nonlinear maturation patterns. MCT1 and CD147 membrane protein 
exhibited low expression at birth, with expression increasing three-fold by PND14, followed by a decline in 
expression at sexual maturity. MCT4 mRNA had highest expression at PND 1, with decreasing expression towards 
sexual maturity. In contrast, MCT4 membrane protein exhibited minimal expression from birth through weaning 
before a 10-fold surge at PND35, whereupon there was a sharp decline in expression at PND42. There was a 
significant positive correlation between MCT1 and CD147 whole cell and membrane expression, while MCT4 
membrane expression demonstrated a weak negative correlation with CD147. Conclusion: Our study elucidates 
the transcriptional and translational maturation patterns of MCT1, MCT4 and CD147 expression, with isoform-
dependent differences in the liver. Changes in transporter expression during development may greatly influence 





Maturation of drug elimination pathways contributes 
to the wide range of inter-individual variability in 
drug disposition observed in pediatric populations. 
Clinical pharmacokinetic studies have identified 
post-natal age as a significant factor influencing 
clearance, with hepatic and renal elimination 
representing the primary mechanisms of drug 
clearance (1, 2). Developmental change in hepatic 
drug clearance are governed by maturation of 
metabolism and drug transport pathways. While 
maturation of drug metabolizing enzymes (3), and 
major hepatic drug transporters (4) have been 
extensively studied in multiple species, there is 
limited data evaluating the maturation of 
monocarboxylate transporters in the liver.  
Monocarboxylate transporters are involved in 
the active transport of essential nutrients and 
pharmaceutical agents, including lactate, pyruvate, 
butyrate and ketone bodies, nicotinate, valproic acid,  
 
nateglinide, salicylate, atorvastatin, and γ-
hydroxybutyrate (GHB) (5-7). There are two 
monocarboxylate transporter families, SLC16A and 
SLC5A; however, only proton-dependent 
monocarboxylate transporters (MCTs) encoded by 
SLC16A are expressed in the liver. There are 14 
members in the MCT family with MCT1 through 4 
(SLC16A1, SLC16A7, SLC16A8 and SLC16A3) 
involved in proton-coupled transport with 
overlapping substrate specificity (5, 8). MCT1 and 4, 
the primary MCTs expressed in the liver, are sorted 
and inserted into the basolateral plasma membrane 
of hepatocytes through their association with the 
ancillary protein CD147 (9). 
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MCTs function as bidirectional transporters with 
directional flux of MCT substrates governed by the 
pH gradient (10), with rate of transport also 
dependent on MCT and CD147 expression and co-
localization (11). Changes in the regulation or 
trafficking of MCTs leading to differences in 
membrane expression can alter the hepatic transport 
of their substrates, leading to alterations in 
intracellular drug concentrations. Differences in 
hepatic transport may impact overall drug exposure, 
which can lead to toxic or sub-therapeutic drug levels 
during development (2). It is vital to understand the 
maturation of these transporters to optimize 
therapeutic regimens for their substrates. 
There is limited information in the literature on 
the maturation of monocarboxylate transporters in 
tissues related to drug disposition. MCT1 has 
transient embryonic expression in the dorsal and 
lateral anlage of rat cerebral cortex (12), whereas in 
the gluteus medius muscle in horse, MCT1 increases 
and MCT4 is stably expressed with age (13), 
suggesting MCTs are regulated in a tissue-specific 
manner. MCT expression differs based on species, 
with minimal expression of MCT1 in hamster liver, 
whereas MCT1 is the predominant isoform 
expressed in mouse, rat, and human livers (12). 
Proteomic studies of human hepatic MCT1 show 
nonlinear, age-dependent levels of expression (13). 
These studies indicate that MCT maturation should 
be evaluated in individual tissues to identify tissue-
specific maturation patterns of each isoform and the 
potential impact on drug pharmacokinetics. The 
objective of the present study is to quantify age-
dependent hepatic mRNA, total and membrane 
protein expression of MCTs and their ancillary 
protein CD147 in male and female rats, to evaluate 
their developmental regulation with respect to 




Animals and Tissue Collection: All animal 
experiments were approved by the Institutional 
Animal Care and Use Committees of University at 
Buffalo (SUNY) and University of the Pacific. Male 
and female Sprague-Dawley rats (> 21 days of age), 
pregnant females (E14 on arrival) and lactating 
females with litters (post-natal day seven on arrival) 
were obtained from Envigo (USA). For pups less 
than 21 days of age, one male and one female pup 
was removed from each litter at individual post-natal 
time points. Pups were weaned at 21 days of age. 
Rats were group housed (except pregnant females) 
and kept under controlled lighting (12h light/dark 
cycle) and temperature (20 ± 2oC) conditions with 
food and water provided ad libitum. Liver samples 
were collected (N = 3 - 5 per gender per age group) 
from post-natal day (PND) 1 through 42 following 
exsanguination under isoflurane anesthesia, and snap 
frozen in liquid nitrogen with storage at -80oC. Body 
and liver weights are detailed in Figure 1. 
 
Sex Determination: Sex was assigned for pups less 
than PND21 by ano-genital distance at the time of 
tissue collection and was confirmed by PCR. Liver 
(25 mg) was utilized to isolate genomic DNA using 
a PureLink Genomic DNA Mini Kit (Invitrogen) 
following the manufacturer’s instructions. DNA 
concentration and purity was evaluated using a 
Nanodrop (Thermo Scientific). The presence of 
SRY, a Y specific sequence, and β-actin (PCR 
control) were evaluated by end-point PCR following 
a previously published method with minor 
modifications (14). Briefly, 2 μl of genomic DNA 
was combined with AmpliTaq Gold (ThermoFisher) 
and corresponding buffer, 0.2 mM dNTPs, 0.2 μM 
forward and reverse primers (Table 1) with a final 
reaction volume of 25 μl. PCR reactions were run 
separately for each gene. Samples were run through 
a thermal cycle using a T100 Thermal Cycler 
(BioRad) as follows: 1 minute at 95oC, 1 minute at 
52oC, and 1 minute at 72oC with the cycle repeated 
35 times. PCR products were separated on a 1.4% 
agarose gel containing SYBR Safe (Invitrogen) in 
1X TBE buffer, run at 100 V for 45 minutes and 
visualized using ChemiDoc Touch imaging system 
(BioRad). 
qPCR: Liver (10 mg) was homogenized and 
RNA was isolated using a PureLink RNA Mini kit 
(Invitrogen) according to the manufacturer’s 
instructions with a DNase treatment step. RNA 
concentration and purity was assessed using a 
Nanodrop (Thermofisher). RNA stability was 
verified by RNA Flash Gel (Lonza) to visualize 18S 
and 28S rRNA bands. 1000 ng of total RNA was 
added to each 20 μL cDNA synthesis reaction, which 
was reverse transcribed using iScript Reverse 
Transcription Supermix (BioRad). Primer 
sequences, annealing temperatures, product sizes 
and assay validation were previously described (15).  
 








Figure 1: Body [A] and liver weights (normalized to body 
weight) [B] for male and female Sprague-Dawley rats 
from birth to sexual maturity. Data is presented as mean ± 
SD (N = 4 – 5 rats per age and sex). *P < 0.05. 
 
 
Serial dilutions of plasmids (covering 5 to 6 orders 
of magnitude) containing the gene-specific amplicon 
were used as standards to confirm qPCR efficiency 
and to quantify relative gene expression. 
Quantitative analyses of MCT1, MCT4, and CD147 
were performed with iTaq Universal SYBR Green 
Supermix as described previously (15) on a CFX96 
Connect (BioRad) with a standard curve run on every 
plate. The external control Alien RNA (Agilent) was 
utilized for data normalization. All biological 
samples were run in triplicate. The purity of all qPCR 
products was determined by melting curve. Data was 
quantified by 2−ΔΔCT method (16) or in arbitrary units 
based on the standard curve. 
 
Western Blot Analysis: Whole cell extracts were 
generated from 25 mg of rat liver tissue and 500 ul 
of ice-cold radioimmunoprecipitation assay (RIPA) 
lysis buffer containing UltraCruz Protease Inhibitor 
Cocktail (Santa Cruz Biotechnology). Samples were 
briefly homogenized then spun at 13,500 rpm in a 
4oC microcentrifuge to collect protein supernatants. 
Soluble cytosolic and total membrane fractions were 
isolated from 25 mg liver samples using a 
Calbiochem ProteoExtract Native Membrane 
Protein Extraction Kit (EMD-Millipore) following 
the manufacturer’s instructions. Protein 
concentrations were calculated using the Pierce BCA 
Protein Assay kit (Thermo Fisher Scientific). MCT1, 
MCT4 and CD147 protein expression was quantified 
using western blot analysis of whole cell extract or 
membrane fraction. Samples (10 μg whole cell 
extract or 5 μg membrane fraction) were mixed with 
2x Laemmli sample buffer (BioRad) and heated at 
37°C for 30 minutes, then loaded onto 10% TGX 
Fastcast acrylamide gels (Biorad) and separated via 
SDS-PAGE at 200V for approximately 45 minutes. 
Following transfer onto nitrocellulose membranes at 
100V for 25 minutes, membranes were blocked in 
5% nonfat milk in phosphate-buffered saline with 
Tween 20 (PBST) for 1 hour at ambient temperature, 
then incubated for 16 hours at 4oC under gentle 
rocking with anti-MCT1 (1:1350, EMD Millipore), 
anti-MCT4 (1:1000, Santa Cruz Biotechnology), 
anti-CD147 (1:5000, Santa Cruz Biotechnology), or 
anti-Na+/K+ ATPase (1:1000, Santa Cruz 
Biotechnology). All antibodies were formulated in 
Table 1: Primer sequences and amplicon size for sex determination assay from (14). 
Primer Primer Sequence Amplicon Size (bp) 
B-Actin Forward AGCCATGTACGTAGCCATCC 
220 
B-Actin Reverse TGTGGTGGGAAGCTGTAGC 
SRY Forward TACAGCCTGAGGACATATTA 
317 
SRY Reverse CGACTTTAACCCTTCGATGA 





1% nonfat milk/PBST. After washing three times for 
10 min in PBST, blots were incubated with goat anti-
rabbit IgG horseradish peroxidase-conjugated 
(1:5000 Santa Cruz Biotechnology) or donkey anti-
goat IgG horseradish peroxidase-conjugated 
secondary antibodies (1:10000 EMD Millipore) for 
1 hour at ambient temperature. Following a final 
3×10 min PBST wash, immunoreactive bands were 
visualized using Clarity Western ECL substrate 
(Biorad) and band densities determined using 
ChemiDoc Touch Imaging System (Biorad). 
 
Data Analysis: Data is presented as mean ± standard 
deviation. Data was analyzed in GraphPad Prism 6 
software using one-way analysis of variance 
(ANOVA), followed by Tukey’s HSD post hoc test. 
Differences of p < 0.05 in post-hoc comparison were 
considered to be significant. Pearson correlation 
analysis in GraphPad Prism 6 was used to evaluate 
the relationships between whole cell and membrane 





Sex was assigned at tissue collection by ano-genital 
distance for all pups less than PND21 with a target 
of four males and four females per age group. Based 
on PCR analysis of the SRY sequence, sex 
assignments were accurate for all pups at PND5 and 
later (data not shown). At PND1, the final PCR sex 
assignments yielded three male and five female pups 




Males and females had similar nonlinear 
transcriptional MCT1 profiles during development 
(Figure 3a and 3b). Expression generally increased 
with age, with peak mRNA levels at PND10 in the 
males and PND 14 in females, before decreasing 
incrementally towards PND42. In males (Figure 3c), 
MCT1 whole cell protein expression was lowest at 
PND1, before increasing gradually with the highest 
expression observed at PND14, before reverting to 
expression levels consistent with neonatal animals at 
adolescence (PND42). A similar trend was observed 
in the females (Figure 3d), although expression was 
higher at PND1 and lower at PND42 as compared to 
the males. Similar patterns were observed for MCT1 
membrane expression (Figure 3e and 3f), with 
reduced expression at PND1 and PND42, and 
significantly higher expression at PND14 and 
PND18 in the males and females, with the males also 
having significantly increased expression at PND10.  
 
MCT4 Expression 
Males and females had similar linear transcriptional 
MCT4 profiles during development (Figure 4a and 
4b), with the highest levels in neonatal rats at PND1, 
3, 5, and 7, before decreasing incrementally with age 
towards PND42 (adolescents). This differed from the 
observed patterns for MCT1 suggesting transporter-
specific developmental regulation. MCT4 
expression was undetectable in whole cell protein 
samples over the age range evaluated for both sexes. 
In males and females, membrane protein was 
minimally expressed at PND1, before increasing 
incrementally to peak at PND35, before decreasing 
drastically at PND42 (Figure 4c and 4d).
 
 
Figure 2: PCR confirmation of sex assignments by ano-genital distance. Genomic DNA was isolated from the liver and SRY 
(317 bp) was utilized to confirm the presence of the Y chromosome. B-actin (220 bp) served as a PCR control, and PND 21 
animals served as positive controls for sex assignments. 






Males and females demonstrated nonlinear 
developmental expression patterns for both whole 
cell and membrane protein.  In males, CD147 whole 
protein expression was low at PND1 and increased 
to peak levels at PND14 and PND18 (approximately 
three times higher expression), before experiencing 
a decrease in expression levels towards PND42 
(Figure 5a). In females, CD147 expression was low 
at PND1, before increasing significantly to its 
highest levels at PND14, before decreasing again to 
neonatal levels at PND42 (Figure 5b). While males 
and females had similar expression levels at PND1, 
males had higher whole cell CD147 expression at 
PND42 compared to PND1, and to females at 
PND42.  Membrane protein expression 
demonstrated similar expression pattern in both 
males and females (Figures 5b and 5c). Males 
demonstrated the highest membrane CD147 
expression at PND14, while females demonstrated 
significantly higher expression at PND10, PND14 
and PND18. Consistent with whole cell CD147 
expression at PND42, males demonstrated 
approximately 2.5 times higher CD147 membrane 
expression as compared to females.  
 
Correlation Analysis 
In the male ontogeny (Figure 6a), comparisons 
between membrane and whole cell MCT1 
expression displayed a significant positive 
correlation with an r value of 0.545. The female 
ontogeny (Figure 6b) had a similar significant 
positive correlation with an r value of 0.587. 
Correlations on the relationship between MCT1 and 
CD147 membrane and whole cell protein expression 
were conducted to investigate membrane trafficking. 
In males (Figure 6c), there was a significant positive 
correlation with an r value of 0.585, while females 
(Figure 6d) had a significant positive correlation; 
however, the r value (0.342) was lower than that 
observed in males. Correlation analysis between 
membrane expression of MCT1 and CD147 
demonstrated strong significant positive correlations 
with r values of 0.8318 and 0.8447 in males and 
females (Figure 6e and 6f). Relationships between 
MCT4 whole cell and membrane expression could 
not be evaluated, as whole cell MCT4 expression 
was not detectable. Correlation analysis was 
conducted to evaluate the trafficking relationship 
between MCT4 and CD147 membrane expression. 
In contrast to MCT1, MCT4 membrane expression 
demonstrated a weak negative correlation with 
membrane CD147 expression; however, this 
relationship was not significant in male or females 




Monocarboxylate transporters are ubiquitously 
expressed in the human body, and studies have 
shown MCTs are associated with the absorption and 
excretion of monocarboxylate drugs in drug 
disposition organs such as the liver, kidneys, and 
intestines. The extent of transport capacity is 
dependent on MCT membrane protein expression, 
with changes in expression altering drug disposition 
in cells and tissues. However, there is limited data 
regarding the maturation and expression of hepatic 
MCTs relative to age, particularly during pediatric 
development in both males and females. A technical 
obstacle in clinical studies is that hepatic fetal and 
infant tissues are often derived postmortem, with 
confounding factors such as race, sex, disease, and 
polygenic traits, as well as limited sampling size 
presenting barriers to controlled pediatric studies 
(13, 17). To our knowledge, the present work is the 
first analysis of changes in rat hepatic MCT1, MCT4 
and CD147 expression at the mRNA, whole cell, and 
membrane protein level during early stages of 
mammalian growth. Here, we show hepatic MCT1 
and CD147 expression changes in a nonlinear 
fashion from birth to sexual maturity with a 
significant positive correlation between MCT1 and 
CD147 membrane expression. The maturation 
pattern of MCT4 differed from MCT1, with low 
expressions at birth followed by a surge in membrane 
expression at PND35. Further, there was a weak 
negative correlation between MCT4 and CD147 
membrane expression. 






Figure 3: MCT1 mRNA, whole cell and membrane protein expression in males [A, C, E] and females [B, D, F] from birth 
to sexual maturity. A, B. Fold-change in MCT1 mRNA expression in rat liver. C, D. Whole cell MCT1 protein expression in 
the liver with data normalized to Na+/K+ ATPase expression. A positive control sample (pooled liver whole cell sample from 
9 week old male Sprague-Dawley rats) was loaded on each blot. E, F. MCT1 membrane expression in rat liver with data 
normalized to Na+/K+ ATPase expression. A positive control sample (pooled liver whole cell sample from 9 week old male 
Sprague-Dawley rats) was loaded on each blot. Data is presented as mean ± SD (N = 4 – 5 rats per age and sex). *P < 0.05 






Figure 4: MCT4 mRNA, whole cell and membrane protein expression in males [A, C] and females [B, D] from birth to 
sexual maturity. A, B. Fold-change in MCT4 mRNA expression in rat liver relative to PND21 females. C, D. MCT4 membrane 
expression in rat liver with data normalized to Na+/K+ ATPase expression. A positive control sample (pooled liver whole cell 
sample from 9 week old male Sprague-Dawley rats) was loaded on each blot. Data is presented as mean ± SD (N = 4 – 5 rats 
per age and sex). *P < 0.05. 
 
 
MCT1 is responsible for nutrient transport and 
essential for the metabolism of carbohydrates, amino 
acids, and fats. Consequently, dysregulation of 
MCT1 expression is associated with metabolic 
disorders such as obesity and abnormal insulin 
secretion (18), as well as altered drug transport and 
pharmacokinetics. MCT1 expression is detected as 
early as oocyte maturation (19), and knockout of the 
transporter leads to embryonic lethality in mouse 
animal models, indicating its critical role in early 
mammalian development and survival (20). 
Comparisons between human fetal (gestational age 
range of 16.4-37.9 weeks), infant (postnatal age 
range of 0-11.4 weeks, gestational age at birth range 
of 27.1-41 weeks), and adult specimen demonstrated 
nonlinear maturation of MCT1 membrane protein in 
the liver (13), which is consistent with that pattern of 
MCT1 maturation observed in the present study.  
Maturation of mRNA and whole cell protein 
expression of MCT1 was consistent with membrane 
protein expression; however, the moderate positive 
correlation suggests that MCT1 translation does not 
completely account for the transporter’s expression 
at the plasma membrane suggesting that other 
regulatory factors mediate trafficking of MCT1 to 
the cell membrane during development.  






Figure 5: CD147 cell and membrane protein expression in males [A, C] and females [B, D] from birth to sexual maturity. A, 
B. Whole cell CD147 protein expression in the liver with data normalized to Na+/K+ ATPase expression. A positive control 
sample (pooled liver whole cell sample from 9 week old male Sprague-Dawley rats) was loaded on each blot. C, D. CD147 
membrane expression in rat liver with data normalized to Na+/K+ ATPase expression. A positive control sample (pooled liver 
whole cell sample from 9 week old male Sprague-Dawley rats) was loaded on each blot. Data is presented as mean ± SD (N 
= 4 – 5 rats per age and sex). *P < 0.05. 
 
Developmental mRNA expression of MCT4 
diverges from the MCT1 profile, with high mRNA 
expression at birth and decreasing levels towards 
sexual maturity; however, MCT4 protein data 
reverses this trend, with low membrane protein 
expression at early ages until a sudden peak at 
postnatal age 35. The mechanisms underlying this 
discrepancy between MCT4 mRNA and protein 
expression are not completely understood. Other 
reviews have reported the historically poor 
correlation observed between mRNA and ex-vivo 
protein in complex biological samples, which 
complicates data interpretation for transcriptional-
translational model predictions (21). Previous 
studies have shown that endogenous microRNAs, 
miR-29 and miR-124, can degrade MCT1 mRNA or 
inhibit its translation, while let-b7 downregulates 
CD147 expression (22), similar mechanisms could 
explain the discrepancy that we observed between 
MCT4 mRNA and protein expression. miR-29 in 
particular is highly expressed in β islet cells, which 
may explain the diminished amount of MCT1 found 
in pancreas compared to other tissues (23), and MCT 
regulation by miRNA may explain the observed 
tissue differences in expression. While fewer 
regulation studies have been performed on MCT4, 
the transcription factor HIF-1α has been shown to 
upregulate mRNA and protein expression of MCT4 
during hypoxia, but not MCT1 (24). However, the 
mechanisms regulating MCT4 expression under 
normoxic conditions remain to be determined (25). 
Further experiments identifying possible miRNA 
activity and other post-transcriptional modifications 
may explain the dynamic changes in MCT1 and 
MCT4 expression based on maturation, with 
subsequent upregulation and downregulation events 
dependent on MCT isoform, biological sample, and 
tissue-type (26). 






Figure 6: Pearson correlation analysis in males [A, C, E] and females [B, D, F]. A, B. Correlation analysis between MCT1 
whole cell protein and membrane expression. C, D. Correlation analysis between whole cell MCT1 and CD147 expression. 
E, F. Correlation analysis between membrane MCT1 and CD147 expression. (N = 42 males; N = 44 females) 






Figure 7: Pearson correlation analysis between membrane MCT4 and CD147 expression in males [A] and females [B]. (N 
= 42 males; N = 44 females) 
 
 
Unlike hepatic transporters and drug 
metabolizing enzymes, few studies have looked at 
the age-dependent expression of ancillary proteins in 
the liver, or their mechanistic roles in drug 
transporter maturation. The CD147 glycoprotein 
binds to MCT1 and MCT4 and confers basolateral 
sorting onto the heterodimer, facilitating the 
transporter’s localization to the plasma membrane 
where it becomes functionally active (27). Studies 
have shown that increased association between 
MCT1/4 and CD147 enhances plasma membrane 
expression of the transporter (28), whereas 
knockdown or silencing of the chaperone in various 
cells lines and transgenic animal models causes 
decreased MCT1/CD147 association and membrane 
co-localization, as well as overall altered tissue 
distribution (29). CD147 in the rumen of juvenile 
sheep was found to increase linearly based on age 
(30). In our experiment, whole cell CD147 protein is 
expressed at minimal levels at birth, with increasing 
and maximum levels at postnatal ages 14/18 in the 
males and postnatal age 14 in females, then 
decreasing towards neonatal levels upon sexual 
maturity. Membrane levels of CD147 reflect the total 
protein trend, with peak expressions at postnatal age 
14 in both sexes, and there exists strong, positive 
correlation between total and membrane-bound 
CD147 protein expression. Comparison of total 
protein MCT1 and CD147 yielded a significant 
moderate correlation, indicating total translation of 
the ancillary protein has minimal impact on whole 
protein expression of its transporter partner. 
However, we observed a significant strong positive 
correlation when comparing the membrane 
expression of MCT1 and CD147, signifying a strong 
association between the membrane proteins, and 
suggesting the ancillary protein is required as a 
chaperone for proper MCT1 trafficking to the cell 
surface throughout normal mammalian 
development, with a nonlinear expressional pattern 
dependent on age. In contrast, MCT4 membrane 
expression demonstrated a weak negative correlation 
with CD147 membrane expression suggesting that 
CD147 does not determine MCT4 membrane 
expression during development. The present study 
did not evaluate MCT4 membrane localization, 
which may be altered if it is no longer associated 
with CD147. 
Previously, our group described the sex hormone 
dependent regulation and localization of MCT1 and 
MCT4 in the liver, with changes in expression 
between male and female rats, as well as in female 
rats at various stages in their estrus cycle (15). 
Consistent with our previous results, we observed 
variability in hepatic MCT1, MCT4, and CD147 
expression between the males and females in both 
juvenile and sexually mature rats. Males exhibited 
increased MCT1 membrane expression at PND10 
and 18 compared to the females. Similarly, MCT4 
and CD147 membrane protein expression was higher 
in males compared to the females in juvenile rats, 
implicating a sex-specific, sex-hormone independent 
regulatory mechanisms in MCT expression. MCT1, 
MCT4 and CD147 membrane expression was higher 
in males than females at PND42, at which age rats 
will have circulating sex hormones. Increased 





abundance of MCTs and ancillary protein in males 
may result in greater hepatic transport capacity for 
nutrients and pharmaceutical agents compared to 
females, which can lead to increased drug absorption 
and reduced hepatobiliary clearance.    
Our data is consistent with previous clinical 
studies on MCT maturation (13) and suggests several 
avenues for future transporter work. The nonlinearity 
of hepatic MCT1 expression indicates a clear need to 
assess the maturation of drug disposition processes 
to account for inter-individual variability in 
pharmacokinetics in pediatric populations. Drug 
uptake and efflux assays in the liver can also evaluate 
the mechanisms between MCT expression and 
function during development, as well as between 
adolescent male and female populations. 
Furthermore, we can explore the effects of age on the 
expressional changes of MCTs in other drug 
disposition tissues such as the intestines and kidney. 
In conclusion, we have demonstrated differential 
expression of hepatic MCT1, MCT4, and CD147 
during development at the level of mRNA 
transcription, protein translation, and membrane 
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